EGFR and cancer: NQs have been shown to be involved in other molecular mechanisms affecting cancer cells, including (i) the inhibition of human DNA topoisomerases I and II (Topo I and Topo II), which are overexpressed in cancer cells and represent a valid target for anticancer agents [16], (ii) the regulation of p53, (iii) the effect shown on the signal transducer and activator of transcription 3 (STAT3) protein, and (iv) the inhibition of EGFR-NF-kB signaling pathway, the last two both linked to inflammation-associated tumorigenesis.